Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells

Authors: Dongming Liang, Yuanyuan Ma, Jian Liu, Claes Goran Trope, Ruth Holm, Jahn M Nesland, Zhenhe Suo

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

To study whether hypoxia influences the stem-like properties of ovarian cancer cells and their biological behavior under hypoxia.

Method

Ovarian cancer cell lines ES-2 and OVCAR-3 were cultivated in different oxygen tensions for proliferation, cell cycling and invasion analyses. The clonogenic potential of cells was examined by colony formation and sphere formation assays. Stem cell surface markers, SP and CD44bright and CD44dim cells were analyzed by flow cytometry. Protein expression of HIF-1α, HIF-2α, Ot3/4 and Sox2 were investigated by Western blotting.

Results

Both cell lines cultivated at hypoxic condition grew relatively slowly with extended G0/G1 phase. However, if the cells were pre-treated under 1% O2 for 48 hrs before brought back to normoxia, the cells showed significantly higher proliferation rate with higher infiltration capability, and significant more colonies and spheres, in comparison to the cells always cultivated under normoxia. CD44bright cells expressed significantly higher levels of Oct3/4 and Sox2 than the CD44dim cells and formed significantly more clones and spheres examined in vitro. Hypoxic treatment of the cells resulted in stronger CD44 expression in both cell lines, and stronger CD133 expression in the OVCAR-3 cell line. In parallel with these findings, significantly increased number of side population (SP) cells and up-regulated expression of Oct3/4 and Sox2 in both ES-2 and OVCAR-3 cell lines were observed.

Conclusion

We conclude that ovarian cancer cells survive hypoxia by upgrading their stem-like properties through up-regulation of stemness-related factors and behave more aggressively when brought back to higher oxygen environment.
Appendix
Available only for authorised users
Literature
1.
Higgins LH, Withers HG, Garbens A, Love HD, Magnoni L, Hayward SW, Moyes CD: Hypoxia and the metabolic phenotype of prostate cancer cells. Biochim Biophys Acta. 2009, 1787 (12): 1433-1443. 10.1016/j.bbabio.2009.06.003.CrossRefPubMed
2.
Jensen RL: Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol. 2009, 92 (3): 317-335. 10.1007/s11060-009-9827-2.CrossRefPubMed
3.
Selvendiran K, Bratasz A, Kuppusamy ML, Tazi MF, Rivera BK, Kuppusamy P: Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. Int J Cancer. 2009, 125 (9): 2198-2204. 10.1002/ijc.24601.CrossRefPubMedPubMedCentral
4.
Sooriakumaran P, Kaba R: Angiogenesis and the tumour hypoxia response in prostate cancer: a review. Int J Surg. 2005, 3 (1): 61-67. 10.1016/j.ijsu.2005.03.013.CrossRefPubMed
5.
Vaupel P, Briest S, Hockel M: Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wien Med Wochenschr. 2002, 152 (13–14): 334-342.CrossRefPubMed
6.
Majmundar AJ, Wong WJ, Simon MC: Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell. 2010, 40 (2): 294-309. 10.1016/j.molcel.2010.09.022.CrossRefPubMedPubMedCentral
7.
Kingsley LA, Fournier PG, Chirgwin JM, Guise TA: Molecular biology of bone metastasis. Mol Cancer Ther. 2007, 6 (10): 2609-2617. 10.1158/1535-7163.MCT-07-0234.CrossRefPubMed
8.
Feldmann HJ: Oxygenation of human tumors–implications for combined therapy. Lung Cancer. 2001, 33 (Suppl 1): S77-S83.CrossRefPubMed
9.
10.
Alvero AB, Fu HH, Holmberg J, Visintin I, Mor L, Marquina CC, Oidtman J, Silasi DA, Mor G: Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells. 2009, 27 (10): 2405-2413. 10.1002/stem.191.CrossRefPubMedPubMedCentral
11.
Burkert J, Wright NA, Alison MR: Stem cells and cancer: an intimate relationship. J Pathol. 2006, 209 (3): 287-297. 10.1002/path.2016.CrossRefPubMed
12.
Conic I, Dimov I, Tasic-Dimov D, Djordjevic B, Stefanovic V: Ovarian epithelial cancer stem cells. Scientific World J. 2011, 11: 1243-1269.CrossRef
13.
Curley MD, Garrett LA, Schorge JO, Foster R, Rueda BR: Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Front Biosci. 2011, 16: 368-392. 10.2741/3693.CrossRef
14.
Gao Q, Geng L, Kvalheim G, Gaudernack G, Suo Z: Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3. Ultrastruct Pathol. 2009, 33 (4): 175-181.CrossRefPubMed
15.
Hjelmeland AB, Wu Q, Heddleston JM, Choudhary GS, MacSwords J, Lathia JD, McLendon R, Lindner D, Sloan A, Rich JN: Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ. 2011, 18 (5): 829-840. 10.1038/cdd.2010.150.CrossRefPubMed
16.
17.
Mor G, Yin G, Chefetz I, Yang Y, Alvero A: Ovarian cancer stem cells and inflammation. Canc Biol Ther. 2011, 11 (8): 708-713. 10.4161/cbt.11.8.14967.CrossRef
18.
Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN: Hypoxia inducible factors in cancer stem cells. Br J Cancer. 2010, 102 (5): 789-795. 10.1038/sj.bjc.6605551.CrossRefPubMedPubMedCentral
19.
Rizzino A: Sox2 and Oct-3/4: a versatile pair of master regulators that orchestrate the self-renewal and pluripotency of embryonic stem cells. Wiley Interdiscip Rev Syst Biol Med. 2009, 1 (2): 228-236. 10.1002/wsbm.12.CrossRefPubMedPubMedCentral
20.
Peng S, Maihle NJ, Huang Y: Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene. 2010, 29 (14): 2153-2159. 10.1038/onc.2009.500.CrossRefPubMed
21.
Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008, 40 (5): 499-507. 10.1038/ng.127.CrossRefPubMedPubMedCentral
22.
Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, et al: CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009, 27 (12): 2875-2883.PubMed
23.
Fong MY, Kakar SS: The role of cancer stem cells and the side population in epithelial ovarian cancer. Histol Histopathol. 2011, 25 (1): 113-120.
24.
Kusumbe AP, Mali AM, Bapat SA: CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature. Stem Cells. 2009, 27 (3): 498-508. 10.1634/stemcells.2008-0868.CrossRefPubMed
25.
Liu T, Cheng W, Lai D, Huang Y, Guo L: Characterization of primary ovarian cancer cells in different culture systems. Oncol Rep. 2010, 23 (5): 1277-1284.PubMed
26.
Slomiany MG, Dai L, Tolliver LB, Grass GD, Zeng Y, Toole BP: Inhibition of Functional Hyaluronan-CD44 Interactions in CD133-positive Primary Human Ovarian Carcinoma Cells by Small Hyaluronan Oligosaccharides. Clin Cancer Res. 2009, 15 (24): 7593-7601. 10.1158/1078-0432.CCR-09-2317.CrossRefPubMedPubMedCentral
27.
Cannistra SA, DeFranzo B, Niloff J, Ottensmeir C: Functional heterogeneity of CD44 molecules in ovarian cancer cell lines. Clin Cancer Res. 1995, 1 (3): 333-342.PubMed
28.
Hu L, McArthur C, Jaffe RB: Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 2010, 102 (8): 1276-1283. 10.1038/sj.bjc.6605626.CrossRefPubMedPubMedCentral
29.
Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK: Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA. 2006, 103 (30): 11154-11159. 10.1073/pnas.0603672103.CrossRefPubMedPubMedCentral
30.
Li Y, Bhuiyan M, Sarkar FH: Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. Int J Oncol. 1999, 15 (3): 525-533.PubMed
31.
Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17 (10): 1253-1270. 10.1101/gad.1061803.CrossRefPubMedPubMedCentral
32.
Ji L, Liu YX, Yang C, Yue W, Shi SS, Bai CX, Xi JF, Nan X, Pei XT: Self-renewal and pluripotency is maintained in human embryonic stem cells by co-culture with human fetal liver stromal cells expressing hypoxia inducible factor 1alpha. J Cell Physiol. 2009, 221 (1): 54-66. 10.1002/jcp.21826.CrossRefPubMed
33.
Lee EY, Xia Y, Kim WS, Kim MH, Kim TH, Kim KJ, Park BS, Sung JH: Hypoxia-enhanced wound-healing function of adipose-derived stem cells: increase in stem cell proliferation and up-regulation of VEGF and bFGF. Wound Repair Regen. 2009, 17 (4): 540-547. 10.1111/j.1524-475X.2009.00499.x.CrossRefPubMed
34.
Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S: Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell. 2009, 5 (3): 237-241. 10.1016/j.stem.2009.08.001.CrossRefPubMed
35.
Zhao T, Zhang CP, Liu ZH, Wu LY, Huang X, Wu HT, Xiong L, Wang X, Wang XM, Zhu LL, et al: Hypoxia-driven proliferation of embryonic neural stem/progenitor cells–role of hypoxia-inducible transcription factor-1alpha. FEBS J. 2008, 275 (8): 1824-1834. 10.1111/j.1742-4658.2008.06340.x.CrossRefPubMed
36.
Chen J, Imanaka N, Chen J, Griffin JD: Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer. 2010, 102 (2): 351-360. 10.1038/sj.bjc.6605486.CrossRefPubMed
37.
Denny WA: Hypoxia-activated prodrugs in cancer therapy: progress to the clinic. Future Oncol. 2010, 6 (3): 419-428. 10.2217/fon.10.1.CrossRefPubMed
38.
McCarty MF, Barroso-Aranda J, Contreras F: Practical strategies for suppressing hypoxia-inducible factor activity in cancer therapy. Med Hypotheses. 2010, 74 (5): 789-797. 10.1016/j.mehy.2009.12.022.CrossRefPubMed
39.
Semenza GL: Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010, 29 (5): 625-634. 10.1038/onc.2009.441.CrossRefPubMed
40.
Box AH, Demetrick DJ: Cell cycle kinase inhibitor expression and hypoxia-induced cell cycle arrest in human cancer cell lines. Carcinogenesis. 2004, 25 (12): 2325-2335. 10.1093/carcin/bgh274.CrossRefPubMed
41.
Yoshiba S, Ito D, Nagumo T, Shirota T, Hatori M, Shintani S: Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G(1) phase cell cycle arrest. Oral Oncol. 2009, 45 (2): 109-115. 10.1016/j.oraloncology.2008.04.002.CrossRefPubMed
42.
Huang L, Ao Q, Zhang Q, Yang X, Xing H, Li F, Chen G, Zhou J, Wang S, Xu G, et al: Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha. J Cancer Res Clin Oncol. 2010, 136 (3): 447-456. 10.1007/s00432-009-0675-4.CrossRefPubMed
43.
De Bock K, Mazzone M, Carmeliet P: Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?. Nat Rev Clin Oncol. 2011, 8 (7): 393-404. 10.1038/nrclinonc.2011.83.CrossRefPubMed
44.
Henze AT, Acker T: Feedback regulators of hypoxia-inducible factors and their role in cancer biology. Cell Cycle. 2010, 9 (14): 2749-2763. 10.4161/cc.9.14.12249.CrossRefPubMed
45.
Cannito S, Novo E, Compagnone A, Valfre di Bonzo L, Busletta C, Zamara E, Paternostro C, Povero D, Bandino A, Bozzo F, et al: Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis. 2008, 29 (12): 2267-2278. 10.1093/carcin/bgn216.CrossRefPubMed
46.
Gort EH, Groot AJ, van der Wall E, van Diest PJ, Vooijs MA: Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr Mol Med. 2008, 8 (1): 60-67. 10.2174/156652408783565568.CrossRefPubMed
47.
Hashimoto O, Shimizu K, Semba S, Chiba S, Ku Y, Yokozaki H, Hori Y: Hypoxia Induces Tumor Aggressiveness and the Expansion of CD133-Positive Cells in a Hypoxia-Inducible Factor-1alpha-Dependent Manner in Pancreatic Cancer Cells. Pathobiology. 2011, 78 (4): 181-192. 10.1159/000325538.CrossRefPubMed
48.
Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, et al: Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene. 2009, 28 (45): 3949-3959. 10.1038/onc.2009.252.CrossRefPubMed
49.
Louie E, Nik S, Chen JS, Schmidt M, Song B, Pacson C, Chen XF, Park S, Ju J, Chen EI: Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Canc Res. 2010, 12 (6): R94-10.1186/bcr2773.CrossRef
50.
Valorani MG, Germani A, Otto WR, Harper L, Biddle A, Khoo CP, Lin WR, Hawa MI, Tropel P, Patrizi MP, et al: Hypoxia increases Sca-1/CD44 co-expression in murine mesenchymal stem cells and enhances their adipogenic differentiation potential. Cell Tissue Res. 2010, 341 (1): 111-120. 10.1007/s00441-010-0982-8.CrossRefPubMed
51.
Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H, Taniguchi H: Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006, 44 (1): 240-251.CrossRefPubMed
52.
Hiraga T, Ito S, Nakamura H: Side population in MDA-MB-231 human breast cancer cells exhibits cancer stem cell-like properties without higher bone-metastatic potential. Oncol Rep. 2011, 25 (1): 289-296.PubMed
53.
Zhu P, Ning Y, Yao L, Chen M, Xu C: The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia. J Exp Clin Cancer Res. 2010, 29: 124-10.1186/1756-9966-29-124.CrossRefPubMedPubMedCentral
54.
Pescador N, Villar D, Cifuentes D, Garcia-Rocha M, Ortiz-Barahona A, Vazquez S, Ordonez A, Cuevas Y, Saez-Morales D, Garcia-Bermejo ML, et al: Hypoxia promotes glycogen accumulation through hypoxia inducible factor (HIF)-mediated induction of glycogen synthase 1. PLoS One. 2010, 5 (3): e9644-10.1371/journal.pone.0009644.CrossRefPubMedPubMedCentral
55.
Kolenda J, Jensen SS, Aaberg-Jessen C, Christensen K, Andersen C, Brunner N, Kristensen BW: Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J Neurooncol. 2011, 103 (1): 43-58. 10.1007/s11060-010-0357-8.CrossRefPubMed
56.
Davis SF, Hood J, Thomas A, Bunnell BA: Isolation of adult rhesus neural stem and progenitor cells and differentiation into immature oligodendrocytes. Stem Cells Dev. 2006, 15 (2): 191-199. 10.1089/scd.2006.15.191.CrossRefPubMed
57.
Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE: Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis. 2005, 26 (2): 495-502.CrossRefPubMed
58.
Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, Hu CJ, Labosky PA, Simon MC, Keith B: HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 2006, 20 (5): 557-570. 10.1101/gad.1399906.CrossRefPubMedPubMedCentral
Metadata
Title
The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells
Authors
Dongming Liang
Yuanyuan Ma
Jian Liu
Claes Goran Trope
Ruth Holm
Jahn M Nesland
Zhenhe Suo
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-201

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

Biomarkers for antitumor activity of bevacizumab in gastric cancer models

Research article

L-DOPA decarboxylase mRNA expression is associated with tumor stage and size in head and neck squamous cell carcinoma: a retrospective cohort study

Research article

Use of a chemically induced-colon carcinogenesis-prone Apc-mutant rat in a chemotherapeutic bioassay

Research article

Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer

Research article

DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1

Research article

In vitro and in vivoanti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits